10-KPeriod: FY2024

VERTEX PHARMACEUTICALS INC / MA Annual Report, Year Ended Dec 31, 2024

Filed February 13, 2025For Securities:VRTX

Summary

Vertex Pharmaceuticals Inc. (VRTX) reported strong financial performance for the fiscal year ending December 30, 2024, with net product revenues reaching $11.0 billion, a 12% increase year-over-year, driven primarily by robust global demand for its cystic fibrosis (CF) medicine, TRIKAFTA/KAFTRIO, and successful label expansions. The company expanded its CF portfolio with the FDA approval of ALYFTREK in December 2024, a once-daily triple combination therapy that demonstrates non-inferiority to TRIKAFTA and offers improved sweat chloride levels. Vertex also saw its TRIKAFTA label expand to include 94 additional CFTR mutations, broadening patient eligibility. Beyond CF, Vertex made significant strides in other therapeutic areas, including the U.S. FDA approval of JOURNAVX in January 2025 for moderate-to-severe acute pain, and continued progress with CASGEVY for sickle cell disease and transfusion-dependent beta thalassemia, with over 50 authorized treatment centers activated globally. The company continues to invest heavily in its diverse pipeline, with advancements in programs for APOL1-mediated kidney disease, IgA nephropathy, Type 1 Diabetes, and various pain indications. Despite increased operating expenses due to R&D investments and commercial launches, Vertex maintains a strong financial position, though its cash reserves saw a decrease following the acquisition of Alpine Immune Sciences and share repurchases.

Financial Highlights

49 data points
Beta

Revenue

$11.02B

86.1% Gross Margin

Net Income

-$535.60M

-4.9% Net Margin

EPS (Diluted)

$-2.08

Total Assets

$22.53B

Cash & Equivalents

$4.57B

Free Cash Flow

-$790.30M

Financial Statements
Beta
Revenue$11.02B
Cost of Revenue$1.53B
Gross Profit$9.49B
SG&A Expenses$1.46B
Operating Expenses$11.25B
Operating Income-$232.90M
Net Income-$535.60M
EPS (Basic)$-2.08
EPS (Diluted)$-2.08
Shares Outstanding (Basic)257.90M
Shares Outstanding (Diluted)257.90M

Key Highlights

  • 1Net product revenues increased by 12% to $11.0 billion in 2024, primarily driven by TRIKAFTA/KAFTRIO.
  • 2FDA approval of ALYFTREK in December 2024 for cystic fibrosis, expanding the company's CF medicine portfolio.
  • 3TRIKAFTA's label expanded in December 2024 to include 94 additional non-F508del CFTR mutations, increasing patient eligibility.
  • 4Received FDA approval for JOURNAVX in January 2025 for moderate-to-severe acute pain, marking its entry into the pain market.
  • 5CASGEVY, a gene-editing therapy for sickle cell disease and beta thalassemia, has seen global uptake with over 50 authorized treatment centers activated.
  • 6Significant investment in R&D, including the acquisition of Alpine Immune Sciences, contributing to a diverse pipeline across multiple therapeutic areas.
  • 7Total operating costs and expenses increased by 86% due to substantial investments in R&D, commercial launches, and the Alpine acquisition.

Frequently Asked Questions

Vertex's revenue growth is primarily driven by its cystic fibrosis (CF) franchise, particularly TRIKAFTA/KAFTRIO, which has seen strong global demand and label expansions. The recent approval and launch of ALYFTREK and JOURNAVX, as well as the ongoing commercialization of CASGEVY, are also expected to contribute significantly to future revenue growth.

Key pipeline developments include the FDA approval of ALYFTREK for CF, the expanded label for TRIKAFTA for CF, and the FDA approval of JOURNAVX for acute pain. Vertex is also advancing programs in APOL1-mediated kidney disease (inaxaplin), IgA nephropathy (povetacicept), Type 1 Diabetes (zimislecel and VX-264), and pain indications (VX-993).

Vertex's total cash, cash equivalents, and marketable securities decreased to $11.2 billion in 2024 from $13.7 billion in 2023, primarily due to the $5.0 billion acquisition of Alpine Immune Sciences and share repurchases. The company continues to generate operating cash flows and expects its existing liquidity to be sufficient for the next twelve months. Vertex also maintains a $500 million revolving credit facility, which was undrawn as of December 31, 2024.

Key risks include the inability to successfully develop and commercialize additional products, reliance on CF medicines for a substantial portion of revenue, competition from other companies, potential safety issues with products, challenges in obtaining and maintaining reimbursement from third-party payors, and risks associated with manufacturing and supply chains for complex cell and genetic therapies.